Table 1 Demographic and clinical features of study subjects
Characteristic | 16S N = 701a | RNA N = 661a | WGS N = 811a |
|---|---|---|---|
Age At Diagnosis | 64 (57, 72) | 64 (57, 72) | 65 (58, 72) |
Unknown | 0 | 0 | 4 |
Sex | |||
Female | 563 (80%) | 529 (80%) | 639 (79%) |
Male | 138 (20%) | 132 (20%) | 172 (21%) |
Ancestry | |||
African (AFR) | 2 (0.3%) | 0 (0%) | 4 (0.5%) |
American (AMR) or Mixed | 38 (5.4%) | 39 (5.9%) | 28 (3.5%) |
East Asian (EAS) | 388 (55%) | 354 (54%) | 338 (42%) |
European (EUR) | 272 (39%) | 267 (40%) | 441 (54%) |
Unknown | 1 | 1 | 0 |
Study Site | |||
Connecticut, USA | 0 (0%) | 0 (0%) | 22 (2.7%) |
Florida, USA | 0 (0%) | 0 (0%) | 11 (1.4%) |
Hong Kong | 132 (19%) | 130 (20%) | 113 (14%) |
IARC (Serbia, Czech Republic, Romania, Poland, Russia) | 204 (29%) | 195 (30%) | 190 (23%) |
Lima, Peru | 4 (0.6%) | 4 (0.6%) | 0 (0%) |
Massachusetts, USA | 0 (0%) | 0 (0%) | 26 (3.2%) |
Mexico City, Mexico | 14 (2.0%) | 16 (2.4%) | 0 (0%) |
Minnesota, USA | 12 (1.7%) | 13 (2.0%) | 13 (1.6%) |
New York, USA | 12 (1.7%) | 11 (1.7%) | 13 (1.6%) |
Nice, France | 26 (3.7%) | 44 (6.7%) | 53 (6.5%) |
Quebec, Canada | 0 (0%) | 0 (0%) | 113 (14%) |
Taiwan | 218 (31%) | 202 (31%) | 184 (23%) |
Toronto, Canada | 71 (10%) | 39 (5.9%) | 68 (8.4%) |
Valencia, Spain | 8 (1.1%) | 7 (1.1%) | 5 (0.6%) |
Stage | |||
I | 407 (61%) | 368 (59%) | 496 (64%) |
II | 115 (17%) | 113 (18%) | 131 (17%) |
III | 108 (16%) | 107 (17%) | 120 (15%) |
IV | 38 (5.7%) | 39 (6.2%) | 30 (3.9%) |
Unknown | 33 | 34 | 34 |
Histology | |||
Adenocarcinoma | 621 (89%) | 584 (88%) | 695 (86%) |
Adenosquamous carcinoma | 12 (1.7%) | 9 (1.4%) | 11 (1.4%) |
Carcinoid tumor | 23 (3.3%) | 23 (3.5%) | 58 (7.2%) |
Squamous cell carcinoma | 36 (5.1%) | 36 (5.4%) | 34 (4.2%) |
Other | 9 (1.3%) | 9 (1.4%) | 13 (1.6%) |
